Abeona therapeutics announces issuance of u.s. patent for aim™ capsids

New york and cleveland, jan. 15, 2020 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced that the united states patent and trademark office (uspto) issued a patent covering next-generation adeno-associated virus (aav) capsids generated using the university of north carolina’s (unc) aim™ vector platform and that the uspto allowed the claims of a companion patent application, which will issue in the next several weeks.  both patents are exclusively licensed by the company from unc.
ABEO Ratings Summary
ABEO Quant Ranking